Skip to content

Evonik bets big on China with biotech skincare innovations and cost cuts

From rice bran emulsifiers to a Shanghai R&D hub, Evonik's bold China strategy blends innovation with tough cost-cutting. Can it balance growth and layoffs?

The image shows the inside of a store filled with lots of different types of cosmetics, including...
The image shows the inside of a store filled with lots of different types of cosmetics, including bottles, boxes, and other objects arranged in racks. There are also screens on the walls, an air conditioner, lights on the ceiling, and glass doors. Through the glass doors, we can see a person, a car, and a building, suggesting that this store is part of a global beauty brand that has recently opened in Dubai.

Evonik bets big on China with biotech skincare innovations and cost cuts

Evonik has unveiled a series of major moves in its Beauty & Personal Care division, with a strong focus on the Chinese market. At the PCHi trade fair in Hangzhou, the company showcased new biotech-driven skincare innovations tailored for local consumers. Meanwhile, a sweeping efficiency program aims to cut costs by €400 million annually, including up to 2,000 job reductions by 2026.

The German specialty chemicals group highlighted several new products at the event. Among them was symbio®muls Aquasoft MB, an emulsifier made from rice bran and optimised for Chinese skin types. This innovation earned a nomination for the PCHi Fountain Award. Another standout was SPHINOX® Vively, a ceramide-based solution designed to strengthen the skin barrier. The company also introduced X50 NeoSyno-Col®, dubbed the 'Cosmetic Drone', which combines two peptides to enhance fibroblast activity and improve skin elasticity.

Evonik's commitment to China was further underlined by the announcement of a new **Asia Beauty Science & Innovation Center** in Shanghai, set to open by 2026. The facility will accelerate the development of locally adapted products, reinforcing the country's role as a strategic priority. The company has rapidly expanded its portfolio for the region, reflecting growing demand for sustainable and high-performance personal care solutions. The expansion comes alongside a broader cost-cutting initiative. Evonik's **'Tailor Made'** transformation program targets annual savings of around €400 million, with roughly 80% of reductions coming from personnel cuts. Up to 2,000 jobs could be affected as part of the restructuring. Despite this, the company forecasts an adjusted EBITDA of between €1.7 billion and €2.0 billion by 2026.

Evonik's latest innovations and investments signal a push to strengthen its position in China's beauty market. The new Shanghai centre and award-nominated products demonstrate a focus on localised research and development. At the same time, the efficiency drive aims to secure long-term financial stability, with significant savings expected from workforce reductions and operational adjustments.

Latest